
Fulvimac 250mg Injection
Salt Composition: Fulvestrant
Expiry Date: 01/2028
Inclusive of all taxes
1 vial(s) of 5ml
About The Product
Breast Cancer, Chemotherapy
Description
Fulvimac 250mg Injection is used to treat hormone receptor-positive breast cancer in postmenopausal women.It is strictly given under medical supervision.
Fulvimac 250mg Injection contains fulvestrant acts as a selective estrogen receptor degrader (SERD) that inhibits cancer cell growth and proliferation.
Uses
- HR+ Breast Cancer
Side Effects
Fulvimac 250mg Injection is a chemical salt based anticancer medication.Therefore,it has several common side effects like any other medicine.Consult your doctor, if side effects persist for longer period of time.
- Hot flashes
- Nausea
- Vomiting
- Muscle cramps
- Abdominal pain
- Diarrhea
- Skin rashes
- Weakness
- Dizziness
- Edema
- Weight changes
- Headache
- Osteoporosis
- Fatigue
- Mood changes
- Stomach bleeding
- Severe skin reactions
- Blood disorders
- Cardiovascular Problems
How To Use
- Fulvimac 250mg Injection is taken intramuscular, into the buttock muscle from a doctor or an experienced nurse.
- Do not self administer the injection. Follow the doctor's prescribed dosage and time.
How It Works
- Fulvimac 250mg Injection (fulvestrant) acts as a selective estrogen receptor degrader (SERD).
- Fulvestrant binds competitively to estrogen receptors (ER) with affinity similar to estradiol, preventing dimerization, nuclear translocation, and DNA binding, while accelerating ER protein degradation via the proteasome pathway.
Safety Advice
FAQs
Fulvimac 250mg Injection cause harm to growing fetus as well as is teratogenic in nature.
Thus, it is not recommended during pregnancy for treatment.
References
- Osborne, C. K., Wakeling, A., & Nicholson, R. I. (2004). Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. British journal of cancer, 90(1), S2-S6. https://pubmed.ncbi.nlm.nih.gov/15094757/
- Curran, M., & Wiseman, L. (2001). Fulvestrant. Drugs, 61(6), 807-813. https://pubmed.ncbi.nlm.nih.gov/11398912/
- Wardley, A. M. (2002). FULVESTRANT: A REVIEW OF ITS DEVELOPMENT, PRE‐CLINICAL AND CLINICAL DATA. International journal of clinical practice, 56(4), 305-309.
- Johnston, S. J., & Cheung, K. L. (2010). Fulvestrant-a novel endocrine therapy for breast cancer. Current medicinal chemistry, 17(10), 902-914.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
